Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of BG00012 in relapsing-remitting multiple sclerosis
2008-004753-14Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Biogen. Primary endpoint: Long-term safety profile of BG00012. Started Dec 2008; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2008-004753-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004753-14.